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Background: Asthma is a chronic disease afﬂicting
millions of children worldwide. Short-acting β2-agonist
reliever medications and inhaled corticosteroid (ICS)
maintenance therapies are effective treatments; however,
many children remain uncontrolled with short-acting
β2-agonist and ICS treatment, in which case guidelines
recommend adding a long-acting β2-agonist.
Objective: We sought to investigate the safety
proﬁle, tolerability, and pharmacokinetic (PK) and
pharmacodynamic (PD) properties of the long-acting
β2-agonist vilanterol (VI) combined with the ICS
ﬂuticasone furoate (FF) administered via the ELLIPTA
dry powder inhaler (GlaxoSmithKline, London, United
Kingdom) in children aged 5 to 11 years with persis-
tent asthma.
Methods: In this randomized, double-blind, re-
peated-dose, 2-way crossover study, data from 8- to
11-year-old children with asthma were reviewed before
those from 5- to 7-year-old children with asthma.
Patients received once-daily FF/VI, 100/25 mg, or FF,
100 mg, in the morning for 14 days, followed by aZ7-
day washout period before switching to the other
treatment for 14 days; the study duration was r11
weeks. Primary end points were adverse events (AEs),
clinical laboratory measurements, peak expiratory
ﬂow, maximum heart rate, blood pressure, and electro-
cardiographic parameters. Secondary end points com-
prised PK (AUC0–4, Cmax) and PD (serum potassium
[0–4 hours], serum cortisol [0–12 hours], and glucose
[0–4 hours]) parameters on day 14.
Results: Twenty-six children were randomized
(58% boys; mean age, 8.1 years). No clinically signiﬁ-
cant changes in the primary end points were observed.928Five patients reported 4 and 2 AEs with FF/VI and FF
therapy, respectively. After FF/VI or FF treatment, the
geometric mean ratios (90% CIs) for FF AUC0–4 (1.02
[0.86–1.22]) and FF Cmax (0.98 [0.65–1.48]) were
similar. For serum glucose (0–4 hours) concentration,
a difference of 0.50 mM (95% CI, 0.19–0.82 mM) was
observed for FF/VI versus FF; no differences were
observed for other PD parameters. No AEs were judged
to be serious or treatment related. The PK proﬁle of FF
did not seem to be altered by VI and was not affected
by age or sex. The signiﬁcance of an increased serum
glucose level is difﬁcult to judge as measurements were
taken from nonfasted patients. Results can be com-
pared only with active treatment, and the ability to
generalize is limited by the small number of patients in
this single-center study.
Conclusions: Once-daily repeated dosing of FF/VI,
100/25 mg, using the ELLIPTA dry powder inhaler
was as well tolerated as FF, 100 mg, in this small,
selected population of 5- to 11-year-old, mostly
white/caucasian children with persistent asthma. (Clin
Ther. 2014;36:928–939) & 2014 The Authors. Pub-
lished by Elsevier HS Journals, Inc.
Key words: ICS, LABA, pediatric, pharmacody-
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Asthma continues to be a major chronic disease in
children.1,2 Initially, short-acting β2-agonist (SABA)
rescue medication can alleviate symptoms as needed
and maintain asthma control. Loss of asthma control
is associated with more frequent use of rescue medi-
cation, increased symptoms, increased exacerbation
frequency or severity, and reduced lung function.2–4 If
control is not maintained with SABA use, maintenance
therapy is initiated with a low-dose inhaled cortico-
steroid (ICS).2 Many pediatric asthmatic patients
remain uncontrolled despite the addition of ICS
therapy.5,6 In children aged Z5 years with asthma
uncontrolled by SABA and low-dose ICS treatment,
the addition of a long-acting β2-agonist (LABA) is
recommended2 and provides the best overall control
compared with alternatives such as increasing the ICS
dose and adding a leukotriene receptor antagonist.7
In children, ICSs and ICSs/LABAs are typically
dosed twice daily. The ICS ﬂuticasone furoate (FF) is
in development as once-daily monotherapy and to-
gether with the LABA vilanterol (VI) is an ICS/LABA
combination therapy for adults and adolescents with
asthma. Once-daily dosing can improve adherence in
asthmatic patients,8–10 which would be beneﬁcial in
pediatric patients, where adherence is known to be
low11; FF12–14 and VI15 have demonstrated efﬁcacy
and tolerability with once-daily dosing in asthmatic
patients aged Z12 years and are being investigated in
a dedicated pediatric development program. The
safety proﬁles and pharmacokinetic (PK) and phar-
macodynamic (PD) properties of FF16 and VI17
monotherapy have been investigated in crossover
placebo-controlled studies.
This study sought to assess the safety proﬁle of FF/
VI therapy versus that of FF monotherapy and to
determine whether the administration of FF combined
with VI via the ELLIPTA dry powder inhaler (DPI)
(GlaxoSmithKline, London, United Kingdom) affected
the PK or PD properties of FF.
METHODS
Study Population
Boys and girls (premenarchal) aged 5 to 11 years
diagnosed as having asthmaZ6 months before screen-
ing and weighingZ20 kg were enrolled. The inclusion
criteria were controlled asthma (Childhood Asthma
Control Test score of41918 and peak expiratory ﬂow
rate [PEFR] Z75% of predicted); Z4 weeks of stableJune 2014asthma treatment with an ICS (ﬂuticasone propionate,
r400 mg daily, or an equivalent) and a SABA; and no
signiﬁcant medical conditions other than eczema or
rhinitis. The exclusion criteria included the use of
theophyllines, LABAs, or oral β2-agonists; alteration
of asthma therapy within 4 weeks; a history of life-
threatening asthma; exacerbations requiring treatment
with systemic corticosteroids or emergency department
attendance (within 3 months); hospitalization (within
6 months); and visual evidence of oral candidiasis at
screening. This study was approved by local ethics
review committees (Quorum Review IRB, Seattle,
Washington) and was conducted in compliance with
Good Clinical Practice guidelines,19 the Declaration of
Helsinki,20 and GlaxoSmithKline Standard Operating
Procedures for all processes involved. Written
informed consent was provided by a parent/guardian
for each patient and was accompanied by informed
assent from participants aged 7 to 11 years.
Study Design
This was a randomized, double-blind, repeated-
dose, 2-period, crossover, Phase IIa study. Screening
was within 28 days prior to dosing. Patients were
separated into 2 cohorts: cohort I included those aged
8 to 11 years, and cohort II included those aged 5 to 7
years. Per the study protocol, dosing of cohort II
occurred only after analysis of blinded tolerability and
PK data from Z6 patients in cohort I.
Patients were randomized and stratiﬁed by age
(with Z1 patient in each age group) to receive FF/
VI, 100/25 mg, followed by FF, 100 mg, or FF, 100 mg,
followed by FF/VI, 100/25 mg. The treatment periods
were 14 days, separated by a washout period of Z7
days, which was not formally capped. The planned
total study length wasr11 weeks, including screening
and follow-up. Four patients exceeded the study
duration (2  78 days, 1  84 days, and 1  98
days), but this was not judged to have affected the
study outcome. Patients were dosed in the morning at
the clinic on day 1, and tolerability assessments were
performed up to 2 hours postdose. Patients self-dosed
at home under parent/guardian supervision on days 2
to 13 within 1 hour of the original dose time. Parents/
guardians were contacted on days 3, 7, and 10 to
review dosing times, report adverse events (AEs), and
deal with questions. Patients visited the clinic on day
14, were dosed within 1 hour of the original dose
time, and were assessed on tolerability and PK and PD929
Clinical Therapeuticsparameters up to 12 hours postdose. All the treat-
ments were delivered via the ELLIPTA DPI. Day 14
assessments were performed on day 15 if scheduling
was an issue. Follow-up visits were within 7 to 14
days of the ﬁnal dose. Patients continued taking their
existing asthma medications during the run-in, wash-
out, and run-out periods but abstained during the
treatment periods. A SABA, salbutamol, was provided
for as-needed symptomatic relief.
Tolerability Assessments
The AEs and serious AEs were recorded until the
end of follow-up and were classiﬁed as mild, moder-
ate, or severe in intensity. The PEFR measurements
were recorded in triplicate at screening, predose, and
postdose on days 1 (up to 2 hours) and 14 (up to 12
hours); predose at home on days 2 to 13 (study diary
card); and during follow-up. Clinical laboratory val-
ues (hematology, chemistry, and urinalysis), vital signs
(systolic and diastolic blood pressure and heart rate
[HR]), and 12-lead electrocardiograms (ECGs) (QT
corrected using the Fridericia correction [QTcF]) were
also assessed; all the clinical laboratory data were
analyzed at Quest Diagnostics (Valencia, California).
The ECG measurements were recorded at screening,
on day 1 predose and up to 2 hours postdose, on day
14 predose and up to 8 hours postdose, and during
the follow-up visit; results were assessed by Quintiles
(Mumbai, India). Blood samples were taken on day 14
predose and up to 4 hours (PK parameters, potassium,
and glucose) or 12 hours (cortisol) postdose; all the
PK samples were assessed at GlaxoSmithKline (Ware,
United Kingdom). All the clinically signiﬁcant changes
from baseline were followed until resolution or
stabilization.
PK Assessments
Blood samples were collected predose and up to 4
hours postdose on day 14 of each treatment period via
an indwelling catheter. Samples were centrifuged at
1500g for 10 minutes. Plasma samples (150-mL
aliquots) were analyzed for FF after treatment with
FF/VI, 100/25 mg, or FF, 100 mg, by solid phase
extraction using [13C 2H3]-GW685698 as internal
standard, followed by high-performance liquid chro-
matography with mass spectrometry detection using a
TurboIonSpray interface and multiple reaction mon-
itoring using an ABI API 5000 machine (Applied
Biosystems, Waltham, Massachusetts). A gradient930system using 5 mM of ammonium formate and
methanol was run with column ACE 50  2.1 mm,
C18 3 mm (Hichrom Ltd, Berkshire, United Kingdom)
running at 45ºC. The ion transition for FF was m/z
539 to 313. The validation range of the assay was 10 to
1000 pg/mL for FF, and within-run precision, between-
run precision, and bias were allo12%. The lower limit
of quantiﬁcation for FF was 10 pg/mL.
Plasma samples (200-mL aliquots) were analyzed
for VI after treatment with FF/VI, 100/25 mg, by solid
phase extraction using ([2H12]-GW642444 as internal
standard), followed by high-performance liquid chro-
matography with tandem mass spectrometry using an
ABI API 5000 machine. A gradient system using 10 mM
of ammonium formate containing 0.1% formic acid and
acetonitrile containing 0.1% formic acid was run with
column 50  2.1 mm i.d. Hypersil Gold 3 mm (Thermo
Scientiﬁc, Loughborough, United Kingdom) running at
50ºC. The ion transition for VI was m/z 486 to 159. The
validation range of the assay was 10 to 1000 pg/mL for
VI, and within-run precision, between-run precision, and
bias were all r10%. The lower limit of quantiﬁcation
for VI was 10 pg/mL.
Quality controls prepared at 3 different concen-
trations were analyzed with each batch of samples
against separately prepared calibration standards to
assess the day-to-day performance of the assay.
Quality control results from this study met the accept-
ance criteria of no more than one third of the quality
control results deviating from the nominal concen-
tration by 415%, with Z1 quality control result
acceptable at each concentration.
The PK analyses of plasma concentration–time data
were conducted using noncompartmental Model 200
of WinNonlin Professional software, version 5.2
(Pharsight Corp, St Louis, Missouri). The following
parameters were derived: Cmax, tmax, and AUC0–t. The
time of last quantiﬁable plasma concentration (t) was
also reported.
PD Assessments
Blood samples were taken on day 14 via an indwell-
ing catheter; serum cortisol determination samples were
taken predose and then 2, 4, 8, and 12 hours after
dosing. Samples for glucose and potassium analysis
were collected predose and 10 min and 30 minutes and
1, 2, and 4 hours postdose. All the PD samples
were analyzed by Quest Diagnostics. For analysis of
serum cortisol levels, the high-throughput liquidVolume 36 Number 6
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wanted sample components. The detection was per-
formed by the tandem mass spectrometer. The
enzymatic method of analysis for glucose samples
was based on the catalytic action of hexokinase on
glucose and adenosine triphosphate to yield glucose-6-
phosphate.21 The glucose-6-phosphate is then reacted
on by glucose-6-phosphate dehydrogenase with simul-
taneous reduction of nicotinamide adenine dinucleo-
tide to nicotinamide adenine dinucleotide hydride. The
absorbance of the reduced nicotinamide adenine
dinucleotide hydride, which is produced in an amount
equimolar to the concentration of glucose, is read
bichromatically at 340/380 nm. The absorbance value
is then compared with the absorbance produced by a
known calibrator. The result is then printed out
directly in milligrams per deciliter . Serum potassium
levels were measured by using a ﬂow cell with an ion-
selective electrode.22 A statistical analysis was
performed on the weighted mean potassium (0–4
hours) and weighted mean glucose levels (0–4 hours)
on day 14. All the available derived values were used.
A mixed-effects model was ﬁtted with treatment and
period as ﬁxed effects and patient as a random effect.
From these analyses, the difference between the
adjusted means and corresponding 2-sided 95% CIs
for FF/VI relative to FF was estimated.
The HR assessments were made on day 1 predose
and 20 minutes and 1 and 2 hours postdose and on
day 14 predose and 20 minutes and 1, 2, 4, and 8
hours postdose. The mean treatment differences on
days 1 and 14, and their associated 95% CIs, were
constructed.
Exploratory Pharyngometry and Inhalation
Profile Assessments
Pharyngometry and inhalation proﬁles were col-
lected at screening and predose on days 1 and 14 of
each treatment period. Mouth and throat geometry
was measured using acoustic reﬂectance (Eccovision;
Sleep Group Solutions, North Miami Beach, Florida).
Inhalation proﬁles were measured using an instru-
mented blinding box connected to an inhalation
proﬁle recorder (GlaxoSmithKline, Ware, United
Kingdom). Attributes of FF/VI or FF dose emission
from the ELLIPTA DPI were modeled through repli-
cation of selected inhalation proﬁles using an
in vitro simulation method (Electronic Lung [eLung];
GlaxoSmithKline, Ware, United Kingdom)23 and anJune 2014anatomical throat cast. Predictions for the total
emitted dose, ex-throat dose, and mass of ex-throat
dose of particles o2 mm were made for each
patient.
Statistical Methods
The primary end points comprised AEs, clinical
laboratory measurements, PEFR (0–2 hours, day 1; 0–
12 hours, day 14), systolic and diastolic blood
pressure (0–8 hours, day 14), maximum HR (0–
2 hours, days 1 and 14), and ECG parameters,
including QTcF (0–2 hours, days 1 and 14). The
secondary end points included PK parameters and
serum cortisol (0–12 hours, day 14), potassium (0–4
hours, day 14), and glucose (0–4 hours, day 14)
weighted mean levels.
Twenty-six patients were randomized to ensure
that Z20 patients completed the study, including
Z1 child from each age group. No formal sample
size calculation was performed because no formal
hypotheses were tested; sample size was based on
feasibility. If no AEs of major concern were observed
after dosing in 20 patients, then the calculated
probability of the true rate of AEs of major concern
in the whole population of patients, based on the
upper 95% CI for the number of patients, would be
less than 14%.
For maximum HR and QTcF (0–2 hours), differ-
ences between the 2 treatments were investigated
using mixed-effects repeated-measures models. Treat-
ment, period, day, and treatment  day interaction
were ﬁtted as ﬁxed effects, and patient was treated as
a random effect. The difference between the adjusted
means and corresponding 2-sided 95% CIs for FF/VI
relative to FF was estimated for days 1 and 14.
Similarly, each of the 0- to 4-hour weighted mean
potassium and glucose end points on day 14 were
statistically analyzed using a mixed-effects model.
Treatment and period were ﬁtted as ﬁxed effects and
patient as a random effect. Serum cortisol weighted
mean level (0–12 hours) on day 14 was loge-
transformed, and a mixed model was ﬁtted with
treatment and period as ﬁxed effects and patient as
a random effect. For the FF analyte, a mixed-effects
model was ﬁtted on the day 14 loge-transformed Cmax
and AUC0–4 with treatment and period as ﬁxed effects
and patient ﬁtted as a random effect. The ratio and
corresponding 2-sided 90% CI for FF/VI relative to FF
was estimated.931
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Patient Disposition and Baseline Characteristics
Twenty-six patients were enrolled and randomized to
treatment, and 23 completed the study (Figure 1). All ages
between 5 and 11 years were represented in the study with
an approximate sex balance, and most patients (84%) had
mild asthma, ie, well controlled with low-dose ICS therapy
(Global Initiative for Asthma step 2) (Table I).
The most frequently reported concomitant medica-
tion was inhaled ﬂuticasone propionate for asthma,
taken by 18 patients as permitted during the run-in,
washout, and run-out periods. Seven patients took other
concomitant medications for nonasthmatic conditions
that were judged not to have compromised the safety
proﬁle or to have affected the outcome of the study.
Safety Profile and Tolerability Results
Six AEs were reported by 5 patients, and all
resolved during the study; 4 AEs were reported withPatients randomized
N = 26
Patients in safety
population
n = 26*
Patients completing as
planned
n = 23*
Withdrawals
n = 3
Figure 1. Patient disposition. *Cohort I (8–11 years old
study. Cohort II (5–7 years old) comprised 1
fluticasone furoate.
932FF/VI, 100/25 mg, and 2 with FF, 100 mg (Table II).
Events of bronchitis and streptococcal pharyngitis
(both during FF/VI treatment) were of moderate
intensity, and all other AEs were mild. No AEs were
considered to be treatment related. There were no
serious AEs or AEs leading to withdrawal or death.
No clinically signiﬁcant changes in clinical labora-
tory values were observed with FF/VI or FF treatment,
and the mean clinical laboratory values observed
between the 2 therapies were similar. There was no
evidence of a clinically relevant difference in change
from baseline in HR, systolic or diastolic blood
pressure, or ECG measures after 14 days of repeated
dosing with either intervention. Mean PEFRs did not
differ between treatments for predose and postdose
measures on day 1 or 14, and no worsening of PEFR
was observed up to 20 minutes postdose with either
treatment (see Supplemental Table I in the online
version at http://dx.doi.org/10.1016/j.clinthera.2014.1  Protocol deviation
1 began her first
menstrual cycle during
FF, 100 µg, dosing in
treatment 1
1 did not attend Day 14
in treatment period 1
2 Investigator discretions
1 did not attend Day 14
in treatment period 2
owing to a sibling being
born on that day
) comprised 15 patients, 12 of whom completed the
1 patients, all of whom completed the study. FF ¼
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Table I. Patient demographic characteristics.
Characteristic Study Population (N ¼ 26)
Age, y (mean [range]) 8.1 (5–11)
Age, No.
5 y 2
6 y 5
7 y 4
8 y 4
9 y 3
10 y 4
11 y 4
Female sex, No. (%) 11 (42)
Height, cm (mean [range]) 131.8 (113–156)
Weight, kg (mean [range]) 32.56 (20.0–71.8)
BMI, mean (range) 18.13 (14.0–29.5)
Race, No. (%)*
White: caucasian/European heritage 21 (81)
African American/African heritage 3 (12)
White: Arabic/North African heritage 1 (4)
Mixed race: African American/African heritage and white 1 (4)
Asthma severity, No. (%)†
Mild (well-controlled with GINA step 2 low-dose ICSs) 21 (84)
Moderate (well-controlled with GINA step 3 medium-dose ICSs) 4 (16)
BMI ¼ body mass index (calculated as weight in kilograms divided by height in meters squared); GINA ¼ Global Initiative for
Asthma; ICS ¼ inhaled corticosteroid.
*Percentages do not sum to 100% due to rounding.
†n ¼ 25. Disease severity was calculated by assessing the use of concomitant medications during the run-in and washout
periods of the study, during which patients were to continue using the medications that they had used before screening. As a
result, the disease severity of the patient who did not attend the clinic on day 14 of treatment period 1 (and was withdrawn
as a result) is unknown.
A. Oliver et al.03.014). No worsening of mean PEFR compared with
baseline during the 14-day treatment period was seen
for either treatment.
PK Results
Twenty-four patients were included in the FF PK
analysis; 2 did not complete treatment with either FF/
VI or FF and were not included. The FF concentra-
tions were quantiﬁable in most patients for up to 4
hours after the ﬁnal doses of FF/VI and FF on day 14
(Figure 2A). The FF concentrations were not
quantiﬁable in 3 patients for FF/VI and in 5 for FF;
these values were set to 0 in the analysis of results. The
FF Cmax and AUC0–4 values were similar between theJune 20142 treatments (Table III). Individual FF scatterplots of
Cmax or AUC0–4 by age indicate no effect of age on
these individual PK parameters (Figures 2B and 2C).
The FF PK proﬁle was similar after treatment with FF/
VI or FF alone, with an adjusted mean ratio (90% CI)
of 1.02 (0.86–1.22) for AUC0–4, and 0.98 (0.65–1.48)
for FF Cmax.
Twenty-three patients were included in the VI PK
analysis; 3 did not complete treatment with FF/VI and
were not included. As with FF, VI concentrations were
quantiﬁable in most patients up to 4 hours after the
ﬁnal dose of FF/VI on day 14 (Figure 3A); 2 patients
had no quantiﬁable VI concentrations that were set to
0 in the analysis of results. The VI Cmax was observed933
Table II. Number of patients with any AEs.
AE
Patients, No. (%) (N ¼ 25)
FF/VI, 100/25 μg* FF, 100 μg†
Any AE 4 (16) 1 (4)
Headache 1 (4) 0
Upper respiratory
tract infection
0 1 (4)
Conjunctivitis 1 (4) 0
Conjunctivitis viral 0 1 (4)
Bronchitis 1 (4) 0
Streptococcal
pharyngitis
1 (4) 0
AE ¼ adverse event; FF ¼ ﬂuticasone furoate; VI ¼
vilanterol.
*One patient received FF, 100 mg, but was withdrawn
(investigator discretion) before receiving FF/VI, 100/25
mg, and was not included in the FF/VI, 100/25 mg, safety
analysis.
†One patient received FF/VI but was withdrawn (protocol
deviation) before receiving FF, 100 mg, and was not
included in the FF, 100 mg, safety analysis.
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Clinical Therapeuticsa median of 10 minutes after the administration of
FF/VI (Table III). Individual scatterplots of VI Cmax
and AUC0–4 by age indicate no clear effect of age on
these individual PK parameters (Figures 3B and 3C).A
U
C
0–
4 
(p 100
50
0
5 7 9 11
Age (y)
Figure 2. (A) Mean (95% CI) fluticasone furoate
(FF) concentration-time profiles after
once-daily dosing of FF/vilanterol (VI),
100/25 mg, or FF, 100 mg for 14 days.
(B) Scatterplot of day 14 individual FF
Cmax values by age for FF/VI, 100/25
mg, and FF, 100 mg. (C) Scatterplot of
day 14 individual FF AUC0–4 values by
age for FF/VI, 100/25 mg, and FF, 100
mg. LLQ ¼ lower limit of quantification.PD Results
No clinically signiﬁcant differences were observed
in maximum HR and QTcF (0–2 hours) on day 1 or
day 14 between the 2 treatments (Figures 4A and 4B;
see Supplemental Table II in the online version at
http://dx.doi.org/10.1016/j.clinthera.2014.03.014).
Weighted mean serum potassium and cortisol levels,
measured at 0 to 4 hours and 0 to 12 hours,
respectively, were not signiﬁcantly clinically different
between the 2 treatments on day 14 (Figures 4C and
4D; see Supplemental Table II in the online version at
http://dx.doi.org/10.1016/j.clinthera.2014.03.014).
Weighted mean serum glucose levels, assessed over 0
to 4 hours on day 14, were slightly higher after FF/VI
than after FF, with an average difference of 0.50 mM
(95% CI, 0.19– 0.82 mM) (Figure 4E; see934 Volume 36 Number 6
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dx.doi.org/10.1016/j.clinthera.2014.03.014).
Exploratory Pharyngometry and Inhalation
Profile Assessments
Pharyngometry data for 23 patients were available
for assessment. The mean (SD) distance of assessment
(lips to larynx), cross-sectional area, and oropharyng-
eal volume were 19.26 (0.72) cm, 3.76 (2.20) cm2,
and 72.35 (42.44) cm3, respectively, on day 14 of the
FF/VI treatment period and 19.10 (1.00) cm, 3.70
(2.28) cm2, and 71.47 (45.84) cm3 on day 14 of the
FF treatment period. Pressure drop versus time proﬁles
recorded while inhaling across the resistance of the
DPI resulted in an overall mean (SD) peak inspiratory
ﬂow rate (PIFR) for day 14 of 67.4 (16.4) L/min and
64.8 (15.9) L/min for the FF/VI and FF treatment
periods, respectively. No relationship was seen be-
tween PIFR and body mass index, and a weak trend
was observed for a relationship between PIFR and
patient age or height (data not shown). Through use
of the eLung in vitro simulation method, dose emis-
sion attributes of FF and VI delivered via the ELLIPTA
DPI as FF/VI or FF alone were predicted for each
patient. For day 14 data, the mean total emitted dose,
mean ex-throat dose, and mean predicted mass of
particles o2 mm, respectively, were predicted to be
87.6, 25.0, and 6.7 mg for FF when delivered as FF/VI;
20.3, 8.5, and 4.9 mg for VI when delivered as FF/VI;
and 86.3, 24.3, and 6.0 mg for FF when delivered as
FF alone.
DISCUSSION
The results of this study suggest that an inhaled ﬁxed-
dose combination of FF/VI, 100/25 mg, exhibits a
similar tolerability proﬁle as FF, 100 mg, in pediatric
patients aged 5 to 11 years with persistent asthma.
Treatment with FF/VI did not give rise to clinically
signiﬁcant PD effects, and the PK proﬁle of FF was
similar when dosed alone or combined with VI,
suggesting that simultaneous administration of FF/VI
via the ELLIPTA DPI had no adverse effect on the PK
proﬁle of FF in children.
Although more AEs were reported during FF/VI
treatment (n ¼ 4) than during FF monotherapy (n ¼ 2),
none were serious, and the incidence was low. Most
AEs were described as mild in intensity, and all
were typical childhood illnesses (bronchitis, conjunc-
tivitis, headache, streptococcal pharyngitis, and upper935
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936respiratory tract infection); none were judged to be
drug related. Because of the small number of patients
and AEs, it was not possible to make deﬁnitive
deductions regarding rates of AEs. No pattern was
observed indicating a difference in AEs between the 2
treatments.
A variety of systemic PD effects have been associ-
ated with high-dose LABA and high-dose ICS therapy.
Use of LABAs has been associated with increased HR,
QTcF, and serum glucose levels and decreased blood
potassium levels,24 whereas ICS therapy has been
associated with decreased serum cortisol levels and
growth retardation in children.25 We observed no
differences of clinical importance after FF/VI therapy
versus FF monotherapy in HR, QTcF, serum
potassium levels, or serum cortisol levels. A small
increase in weighted mean serum glucose levels (0–4
hours) of 0.5 mM was observed on day 14 with FF/VI
therapy compared with FF therapy. It is difﬁcult to
judge the clinical signiﬁcance of this ﬁnding because
the effect of food intake on glucose levels was not
controlled, and the samples were taken from children
in a nonfasted state. It was observed that owing to the
length of the ﬁrst clinic visit, parents fed their children
before and during subsequent visits, which may
explain some of the variation. Treatment with FF/VI
did not induce any clinically signiﬁcant changes in
glucose levels in nonfasted adults in a recent study of
FF/VI versus ﬂuticasone propionate,26 and in a study
of VI, 25 mg, in pediatric asthmatic patients, no
difference was observed in serum glucose levels
compared with placebo.17
In this study, the PK proﬁle of FF did not differ
markedly for AUC0–4 or Cmax values whether dosed as
monotherapy or as FF/VI, which is consistent with
data previously obtained in adults at higher doses.27,28
Furthermore, the PK proﬁles of FF and VI did not
seem to be affected by age or sex. Because VI was
administered only as FF/VI in this study, the effects of
FF on the PK proﬁle of VI cannot be readily deter-
mined, although no interaction has been seen in
adults.27,28 The small difference in Cmax for VI, which
was 44.2 pg/mL after 14 days of FF/VI therapy in the
present study compared with 97.4 pg/mL after 7 days
of VI monotherapy in a previous pediatric study,17 is
likely to reﬂect interstudy variability because of the
small number of patients. The tmax was comparable
between the 2 studies (12 minutes in the monotherapy
study and 10 minutes in the present study), suggestingVolume 36 Number 6
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A. Oliver et al.that FF therapy does not affect VI absorption, similar
to the lack of interaction seen in adults.27 The PEFR
measurements, included for investigation of the safety
proﬁle and tolerability and not for efﬁcacy, were
similar between the 2 treatments.
This study beneﬁted from a crossover design in
which patients acted as their own controls; a good
sex balance was achieved, and each age between 5
and 11 years was represented byZ1 patient. The low
withdrawal rate (3 of 26 patients) and the collection
of serial blood samples over a 4-hour period for PK
analysis and a 12-hour period for PD analysis
allowed for adequate assessment of these end points.
This study was conducted in well-controlled asth-
matic patients receiving a stable regimen of low or
medium doses of ICS in a single center in 1 country,June 2014ensuring consistency in standard of care between
patients but limiting generalizability. The limitations
of this study include the lack of a placebo control
arm, which was omitted to minimize the risk of
patients developing uncontrolled asthma. This limits
interpretation of the results to the effects of active
therapy only; however, in previous placebo-
controlled trials in pediatric patients, the safety
proﬁles of FF16 and VI17 did not differ markedly
from that of placebo, and the safety proﬁles of FF/VI
and FF in this study are similar to those observed in
the placebo-controlled studies. In addition, because
this study was not designed as a noninferiority study,
the results can be interpreted only in a descriptive
manner. Long-term tolerability and safety issues
could not be addressed in this study owing to the937
Clinical Therapeuticsshort length of the treatment period and because the
small population size was not large enough to
identify any potential rare effects.
CONCLUSIONS
Once-daily dosing of FF/VI, 100/25 mg, for 14 days
seemed to be tolerated as well as FF, 100 mg, in
children aged 5 to 11 years with persistent asthma.
Systemic exposure to FF was similar in patients after
the administration of FF/VI or FF, and there was no
apparent relationship between the age of the patient
and FF or VI Cmax and AUC values. In this small and
nonfasted study, serum glucose levels were slightly
higher in patients after treatment with FF/VI com-
pared with FF; however, no other clinically signiﬁcant
PD effects associated with ICS or LABA treatment
were observed in this study. Data collected from the
eLung suggest that the PIFR achieved by 5- to 11-
year-olds with persistent asthma when inhaling
through the ELLIPTA DPI was sufﬁcient to predict
consistent product performance. Once-daily FF/VI,
100/25 mg, and FF, 100 mg, delivered via the ELLIPTA
DPI are, therefore, potential therapeutic options for
the treatment of children aged 5 to 11 years with
persistent asthma.
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Clinical TherapeuticsSUPPLEMENTAL MATERIALSupplemental Table I. Average clinic visit peak expirator
Day Time Point
FF/VI, 100/25 μg (n
No. Mean (9
1 Baseline 25 219.0 (197
10 min 25 218.8 (196
20 min 25 222.4 (200
1 h 25 223.2 (200
2 h 25 227.0 (203
14 Predose 23 224.8 (201
20 min 23 227.2 (204
2 h 23 235.7 (212
12 h 23 238.9 (214
FF ¼ ﬂuticasone furoate; VI ¼ vilanterol.
Supplemental Table II. Comparison of pharmacodynam
Measure Comparison
Heart rate, bpm FF/VI, 100/25 mg – FF, 100 mcg
QTcF, msec FF/VI, 100/25 mg – FF, 100 mg
Glucose, mML FF/VI, 100/25 mg – FF, 100 mg
Potassium, mM FF/VI, 100/25 mg – FF, 100 mg
Cortisol, mM* FF/VI, 100/25 mg / FF, 100 mg
bpm ¼ beats per minute; FF ¼ ﬂuticasone furoate; QTcF ¼ QT
*Adjusted ratio.
939.e1y flow rate. Data are given as liters per minute.
¼ 25) FF, 100 μg (n ¼ 25)
5% CI) No. Mean (95% CI)
.0–241.0) 25 223.6 (200.1–247.1)
.9–240.7) 25 223.0 (200.2–245.8)
.3–244.5) 25 228.2 (204.8–251.6)
.8–245.6) 25 227.2 (204.9–249.5)
.9–250.1) 25 228.6 (206.2–251.0)
.9–247.6) 24 215.0 (193.6–236.4)
.6–249.7) 24 218.1 (196.1–240.1)
.7–258.6) 24 225.8 (205.2–246.4)
.8–263.1) 24 230.4 (208.2–252.6)ic measures.
Day
Adjusted Means
Test – Reference
Difference of
Adjusted Means
(95% CI of Difference)
1 84.4 – 88.6 –4.2 (–8.8 to 0.4)
14 89.4 – 85.7 3.7 (–1.1 to 8.5)
1 403.3 – 402.2 1.2 (–4.4 to 6.7)
14 404.0 – 404.2 –0.3 (–6.0 to 5.5)
14 5.58 – 5.07 0.50 (0.19 to 0.82)
14 4.06 – 4.15 –0.09 (–0.21 to 0.04)
14 193.77/192.50 1.01 (0.85 to 1.19)
corrected using the Fridericia correction; VI ¼ vilanterol.
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